Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Despite updating knowledge and a growing number of medications for multiple sclerosis (MS), no definite treatment is available yet for patients suffering from progressive forms of the disease. Autologous bone marrow derived mesenchymal stem cell (BM-MSC) transplantation is a promising method proposed as a therapy for MS. Although the safety of these cells has been confirmed in hematological, cardiac and inflammatory diseases, its efficacy in MS treatment is still under study. Patients with progressive MS (expanded disability status scale score: 4.0 –6.50) unresponsive to conventional treatments were recruited for this study. Twenty-five patients [f/m: 19/6, mean age: 34.7±7] received a single intrathecal injection of ex-vivo expanded MSCs (mean dose: 29.5×106 cells). We observed their therapeutic response for 12 months. Associated short-term adverse events of injection consisted of transient low-grade fever, nausea /vomiting, weakness in the lower limbs and headache. No major delayed adverse effect was reported. 3 patients left the study for personal reasons. The mean (SD) expanded disability status scale (EDSS) score of 22 patients changed from 6.1 (0.6) to 6.3 (0.4). Clinical course of the disease (measured by EDSS) improved in 4, deteriorated in 6 and had no change in 12 patients. In MRI evaluation, 15 patients showed no change, whereas 6 patients showed new T2 or gadolinium enhanced lesions (1 lost to follow-up). It seems that MSC therapy can improve/stabilize the course of the disease in progressive MS in the first year after injection with no serious adverse effects. Repeating the study with a larger sample size, booster injections and longer follow-up using a controlled study design is advised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384 · cited 1×
“To have clinically definite MS diagnosis in accordance with the Poser criteria [30], and revised McDonald criteria [31].”
MethodMesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746 · cited 1×
“Modulatory effects on both adaptive and innate immunity [10, 18-20], ameliorating neural damage through paracrine secretions into neural microenvironments [5, 21] or promo-”
BackgroundDefining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Friedenstein, A. J., Chailakhyan, R. K., Latsinik, N. V., Panasyuk, A. F., & Keiliss-Borok, I. V. (1974) · Transplantation · doi:10.1097/00007890-197404000-00001 · Cited by 1,431 · cited 1×
“in 1974 [4], these multipotent bone marrow derived cells with feasible ex-vivo expansion have the potential to regenerate various derivatives of mesodermal cell.”
BackgroundMesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy
Zappia, E., Casazza, S., Pedemonte, E., Benvenuto, F., Bonanni, I., Gerdoni, E., Giunti, D., Ceravolo, A., Cazzanti, F., Frassoni, F., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1496 · Cited by 1,430 · cited 2×
“In addition to their previously perceived neural tissue repair by transdifferentiation into neural cells or limited cell fusion mechanism [5, 6], BM-MSCs are a promising candidate for treatment of progressive MS due to their other capabilities as attested by numerous animal experiments [7-17].”
BackgroundHartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946 · cited 1×
“It is worth noting that neither IFNb reduces disability progression in SPMS, confirmed at 6 months [47], nor Mitoxantrone has significant efficacy in reducing the number of patients having disease progression to EDSS of 7·0 [48].”
BackgroundKarussis, D., Karageorgiou, C., Vaknin-Dembinsky, A., Gowda-Kurkalli, B., Gomori, J. M., Kassis, I., Bulte, J. W. M., Petrou, P., Ben-Hur, T., Abramsky, O., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.248 · Cited by 941 · cited 3×
“The only study which could compare these 2 routes of administration was Karussis’s study [27].”
BackgroundNatural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 905 · cited 1×
“SPMS patients spend 3 years, on average, to have 1 score progression in EDSS from 6 to 7 [45, 46].”
BackgroundAging of mesenchymal stem cell in vitro
Bonab, M. M., Alimoghaddam, K., Talebian, F., Ghaffari, S. H., Ghavamzadeh, A., & Nikbin, B. (2006) · BMC Cell Biology · doi:10.1186/1471-2121-7-14 · Cited by 888 · cited 1×
“The cells’ potency to differentiate to adipocytes and osteocytes lineages was also evaluated as previously described [33].”
Self-citationThe clinico-radiological paradox in multiple sclerosis revisited
Barkhof, F. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00003 · Cited by 726 · cited 2×
“More comprehensive scales like the Multiple Sclerosis Functional Composite (MSFC) could overcome such limitations of EDSS [43] which was not included in our study.”
MethodConnick, P., Kolappan, M., Crawley, C., Webber, D. J., Patani, R., Michell, A. W., Du, M.-Q., Luan, S.-L., Altmann, D. R., Thompson, A. J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70305-2 · Cited by 607 · cited 1×
“Given the accumulating data from preceding studies on MSCT in MS [25-29], the feasibility and safety concerns have declined to a great extent.”
Bai, L., Lennon, D. P., Eaton, V., Maier, K., Caplan, A. I., Miller, S. D., & Miller, R. H. (2009) · Glia · doi:10.1002/glia.20841 · Cited by 546 · cited 2×
“In addition to their previously perceived neural tissue repair by transdifferentiation into neural cells or limited cell fusion mechanism [5, 6], BM-MSCs are a promising candidate for treatment of progressive MS due to their other capabilities as attested by numerous animal experiments [7-17].”
BackgroundGerdoni, E., Gallo, B., Casazza, S., Musio, S., Bonanni, I., Pedemonte, E., Mantegazza, R., Frassoni, F., Mancardi, G., Pedotti, R., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21076 · Cited by 482 · cited 3×
“In addition to their previously perceived neural tissue repair by transdifferentiation into neural cells or limited cell fusion mechanism [5, 6], BM-MSCs are a promising candidate for treatment of progressive MS due to their other capabilities as attested by numerous animal experiments [7-17].”
BackgroundAdipose-Derived Mesenchymal Stem Cells Ameliorate Chronic Experimental Autoimmune Encephalomyelitis
Constantin, G., Marconi, S., Rossi, B., Angiari, S., Calderan, L., Anghileri, E., Gini, B., Dorothea Bach, S., Martinello, M., Bifari, F., et al. (2009) · Stem Cells · doi:10.1002/stem.194 · Cited by 403 · cited 2×
“In addition to their previously perceived neural tissue repair by transdifferentiation into neural cells or limited cell fusion mechanism [5, 6], BM-MSCs are a promising candidate for treatment of progressive MS due to their other capabilities as attested by numerous animal experiments [7-17].”
BackgroundRafei, M., Campeau, P. M., Aguilar-Mahecha, A., Buchanan, M., Williams, P., Birman, E., Yuan, S., Young, Y. K., Boivin, M.-N., Forner, K., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803962 · Cited by 381
Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study
Yamout, B., Hourani, R., Salti, H., Barada, W., El-Hajj, T., Al-Kutoubi, A., Herlopian, A., Baz, E. K., Mahfouz, R., Khalil-Hamdan, R., et al. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.07.013 · Cited by 356 · cited 2×
“It is worth noting that Yamout and colleagues reported a 30% failure in growing sufficient cell number despite repeated BMAs [28].”
BackgroundHuman bone marrow stromal cell treatment improves neurological functional recovery in EAE mice
Zhang, J., Li, Y., Chen, J., Cui, Y., Lu, M., Elias, S. B., Mitchell, J. B., Hammill, L., Vanguri, P., & Chopp, M. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.03.018 · Cited by 341 · cited 2×
“In addition to their previously perceived neural tissue repair by transdifferentiation into neural cells or limited cell fusion mechanism [5, 6], BM-MSCs are a promising candidate for treatment of progressive MS due to their other capabilities as attested by numerous animal experiments [7-17].”
BackgroundKassis, I., Grigoriadis, N., Gowda-Kurkalli, B., Mizrachi-Kol, R., Ben-Hur, T., Slavin, S., Abramsky, O., & Karussis, D. (2008) · Archives of Neurology · doi:10.1001/archneur.65.6.753 · Cited by 339 · cited 3×
“In a similar experience on EAE, Kassis and his colleagues demonstrated that direct injection of MSCs into the brain ventricles outweighed IV administration in terms of neurotrophic and neuroprotective effects [12].”
BackgroundNon-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis
Riordan, N. H., Ichim, T. E., Min, W.-P., Wang, H., Solano, F., Lara, F., Alfaro, M., Rodriguez, J. P., Harman, R. J., Patel, A. N., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-29 · Cited by 324
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases
Uccelli, A., Laroni, A., & Freedman, M. S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70121-1 · Cited by 306 · cited 3×
“Nevertheless the growing number of medication focusing on the pathogenic immune response narrows down the MSCs’ chance to be applied in early multiple sclerosis [24].”
BackgroundThe natural history of secondary progressive multiple sclerosis
Koch, M., Kingwell, E., Rieckmann, P., Tremlett, H., & Neurologists, U. M. C. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.208173 · Cited by 241
Neuroprotective features of mesenchymal stem cells
Uccelli, A., Benvenuto, F., Laroni, A., & Giunti, D. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.01.004 · Cited by 230 · cited 2×
“Modulatory effects on both adaptive and innate immunity [10, 18-20], ameliorating neural damage through paracrine secretions into neural microenvironments [5, 21] or promo-”
BackgroundDoes Mesenchymal Stem Cell Therapy Help Multiple Sclerosis Patients? Report of a Pilot Study.
Bonab, M. M., Yazdanbakhsh, S., Lotfi, J., Alimoghaddom, K., Talebian, F., Hooshmand, F., Ghavamzadeh, A., & Nikbin, B. (2007) · PubMed · doi:10.22034/iji.2007.17180 · Cited by 226
Self-citationFreedman, M. S., Bar-Or, A., Atkins, H. L., Karussis, D., Frassoni, F., Lazarus, H., Scolding, N., Slavin, S., Le Blanc, K., Uccelli, A., et al. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509359727 · Cited by 219
Karussis, D., Kassis, I., Kurkalli, B. G. S., & Slavin, S. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.05.005 · Cited by 193 · cited 1×
“The evidence is in favor of additional local in situ immunomodulatory effect [39] and a better chance of MSCs reaching the lesional regions of CNS through CSF [27], which may compensate for the inconvenience of intrathecal injection.”
BackgroundRole of mesenchymal stem cells in neurogenesis and nervous system repair
Maltman, D. J., Hardy, S. A., & Przyborski, S. A. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.06.008 · Cited by 180 · cited 2×
“In addition to their previously perceived neural tissue repair by transdifferentiation into neural cells or limited cell fusion mechanism [5, 6], BM-MSCs are a promising candidate for treatment of progressive MS due to their other capabilities as attested by numerous animal experiments [7-17].”
BackgroundNeuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo
Lanza, C., Morando, S., Voci, A., Canesi, L., Principato, M. C., Serpero, L. D., Mancardi, G., Uccelli, A., & Vergani, L. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06268.x · Cited by 175
Mesenchymal Stem Cells Instruct Oligodendrogenic Fate Decision on Adult Neural Stem Cells
Rivera, F. J., Couillard‐Despres, S., Pedre, X., Ploetz, S., Caioni, M., Lois, C., Bogdahn, U., & Aigner, L. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0614 · Cited by 164 · cited 2×
“In our previous trial [22], which was the first link of the chain, a mean number of 8.”
BackgroundMesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases
Ben-Ami, E., Berrih-Aknin, S., & Miller, A. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.01.005 · Cited by 164 · cited 1×
“Modulatory effects on both adaptive and innate immunity [10, 18-20], ameliorating neural damage through paracrine secretions into neural microenvironments [5, 21] or promo-”
BackgroundBone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice
Zhang, J., Li, Y., Lü, M., Cui, Y., Chen, J., Noffsinger, L., Elias, S. B., & Chopp, M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20962 · Cited by 154 · cited 2×
“In addition to their previously perceived neural tissue repair by transdifferentiation into neural cells or limited cell fusion mechanism [5, 6], BM-MSCs are a promising candidate for treatment of progressive MS due to their other capabilities as attested by numerous animal experiments [7-17].”
BackgroundAmato, M. P., Ponziani, G., Bartolozzi, M. L., & Siracusa, G. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00143-4 · Cited by 138 · cited 1×
“SPMS patients spend 3 years, on average, to have 1 score progression in EDSS from 6 to 7 [45, 46].”
BackgroundHarris, V., Yan, Q. J., Vyshkina, T., Sahabi, S., Liu, X., & Sadiq, S. A. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.08.036 · Cited by 134 · cited 5×
“confirmed priority of IT injection in EAE [17].”
BackgroundInfluentialGordon, D., Pavlovska, G., Glover, C. P. J., Uney, J. B., Wraith, D. C., & Scolding, N. J. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.10.040 · Cited by 119
Connick, P., Kolappan, M., Patani, R., Scott, M. A., Crawley, C., He, X.-L., Richardson, K., Barber, K., Webber, D. J., Wheeler-Kingshott, C. A., et al. (2011) · Trials · doi:10.1186/1745-6215-12-62 · Cited by 119 · cited 1×
“[26] used a protocol that was previously announced [36] to evaluate the effect of intravenous administration of an average number of 1.”
MethodHuman Mesenchymal Stem Cells Signals Regulate Neural Stem Cell Fate
Bai, L., Caplan, A. I., Lennon, D. P., & Miller, R. H. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9212-x · Cited by 101 · cited 1×
“tion of endogenous neural repair [22, 23], and inhibition of further neural loss through anti-apoptotic effects [21, 24], are all among known neuroprotective characteristics with which MSCs are bestowed and from which the rationale for their use as a therapeutic tool comes.”
BackgroundImmunomodulatory Activity of Mesenchymal Stem Cells
M. Kaplan, J., E. Youd, M., & A. Lodie, T. (2011) · Current Stem Cell Research & Therapy · doi:10.2174/157488811797904353 · Cited by 84 · cited 1×
“Modulatory effects on both adaptive and innate immunity [10, 18-20], ameliorating neural damage through paracrine secretions into neural microenvironments [5, 21] or promo-”
BackgroundRice, C. M., Mallam, E., Whone, A. L., Walsh, P., Brooks, D. J., Kane, N., Butler, S., Marks, D. I., & Scolding, N. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.44 · Cited by 84 · cited 3×
“Given the accumulating data from preceding studies on MSCT in MS [25-29], the feasibility and safety concerns have declined to a great extent.”
BackgroundMethodConcepts of induction and escalation therapy in multiple sclerosis
Rieckmann, P. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70012-7 · Cited by 68 · cited 1×
“Patients who fail to respond to these first-line therapies are usually treated with cytotoxic drugs such as mitoxantrone and cyclophosphamide in order to reset the immune system which helps to delay progression of disability [1, 2].”
BackgroundInterferon for secondary progressive multiple sclerosis: a systematic review
Mantia, L. L., Vacchi, L., Rovaris, M., Di Pietrantonj, C., Ebers, G., Fredrikson, S., & Filippini, G. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303291 · Cited by 61 · cited 1×
“It is worth noting that neither IFNb reduces disability progression in SPMS, confirmed at 6 months [47], nor Mitoxantrone has significant efficacy in reducing the number of patients having disease progression to EDSS of 7·0 [48].”
BackgroundZhang, C., Zhou, C., Teng, J.-J., Zhao, R., & Song, Y. (2009) · Cytotherapy · doi:10.1080/14653240902806986 · Cited by 60 · cited 2×
“IV administration might increase the risk of tumor growth or other currently unknown untoward events because of exposing more cells with injected MSCs [42].”
BackgroundClinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox?
Strasser‐Fuchs, S., Enzinger, C., Ropele, S., Wallner-Blazek, M., & Fazekas, F. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507082354 · Cited by 49 · cited 1×
“Another hypothesis to explain this kind of clinico-radiologic paradox (association of T2-lesions with only very little neuronal damage) studied by Strasser-Fuchs and his colleagues has failed to explain the situation [44].”
Background
Cited by
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Trounson, A., & McDonald, C. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.06.007 · Cited by 1,468
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Mesenchymal stem cell‐derived factors: Immuno‐modulatory effects and therapeutic potential
Volarevic, V., Gazdic, M., Simovic Markovic, B., Jovicic, N., Djonov, V., & Arsenijevic, N. (2017) · BioFactors · doi:10.1002/biof.1374 · Cited by 195
Gharibi, T., Ahmadi, M., Seyfizadeh, N., Jadidi-Niaragh, F., & Yousefi, M. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.01.002 · Cited by 104
Diagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70
Metadata
- Authors
- Mohyeddin Bonab, M., Ali Sahraian, M., Aghsaie, A., Ahmadi Karvigh, S., Massoud Hosseinian, S., Nikbin, B., Lotfi, J., Khorramnia, S., Reza Motamed, M., Togha, M., Hossien Harirchian, M., Beladi Moghadam, N., Alikhani, K., Yadegari, S., Jafarian, S., & Reza Gheini, M.
- Venue
- Current Stem Cell Research & Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-12-02
- Volume
- 7
- Issue
- 6
- Pages
- 407-414
- ISSN
- 1574-888X (ISSN-L)
- OpenAlex
- W2138093663
- Cited by
- 176
- References
- 43
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.